# Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy

> **NCT04508829** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 52 (estimated)

## Conditions studied

- Oropharyngeal Carcinoma

## Interventions

- **DRUG:** Anti-EGFR monoclonal antibody

## Key facts

- **NCT ID:** NCT04508829
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-01-01
- **Primary completion:** 2023-12-01
- **Final completion:** 2023-12-01
- **Target enrollment:** 52 (ESTIMATED)
- **Last updated:** 2022-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04508829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04508829, "Anti-EGFR Therapy With IMRT Concurrent Chemoradiotherapy in Locally Advanced OPC Resistant to Induction Chemotherapy". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT04508829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*